News

NBTS Brain Tumor Clinical Trials Report: Q2 2021 It can be hard to keep track of new clinical trial opportunities opening across the United States, especially as we continue to navigate the public health crisis created by the coronavirus (COVID-19). There are many clinical trials actively enrolling patients, and this report provides a summary of the studies that have recently opened or started […] June 30, 2021

Innovating Brain Tumor Clinical Trials: Lessons Learned During the COVID-19 Experience The global COVID-19 pandemic disrupted nearly every facet of life in 2020, and brain cancer research, particularly clinical trials, was not spared from its impacts. As is often the case, though, with disruption comes the opportunity to innovate. Convening key stakeholders across the brain tumor community, the National Brain Tumor Society (NBTS) has taken stock […] May 7, 2021

NBTS Brain Tumor Clinical Trials Report: Q1 2021 It can be hard to keep track of new clinical trial opportunities opening across the United States, especially during the current public health crisis created by the coronavirus (COVID-19). However, there are many clinical trials still actively enrolling patients, and this report provides a summary of the studies that have recently opened or started for […] April 8, 2021

Remembering Jeff Kolodin It is with deep sadness that we share news of the passing of Jeff Kolodin, former chair of the National Brain Tumor Society (NBTS) Board of Directors, due to the effects of COVID. His commitment to the brain tumor community, magnetic personality, and unstoppable perseverance have been an inspiration to patients, caregivers, researchers, corporate partners, […] April 2, 2021

New Treatment Arms Opening for Patients in NBTS-Funded GBM AGILE Clinical Trial Yesterday, it was announced that the GBM AGILE adaptive clinical trial platform is opening two new treatment arms, with one evaluating Kintara Therapeutics’s chemotherapy, VAL-083, and Kazia Therapeutics’s targeted therapy, paxalisib.  “NBTS has long supported GBM AGILE as a scientifically cutting-edge and more patient-friendly way to develop and evaluate emerging new treatments for patients,” says […] January 7, 2021